keyword
MENU ▼
Read by QxMD icon Read
search

cutaneous adverse effects, drug

keyword
https://www.readbyqxmd.com/read/28340402/eslicarbazepine-acetate-as-a-therapeutic-option-in-a-patient-with-carbamazepine-induced-rash-and-hla-a-31-01
#1
Lara Kay, Laurent M Willems, Johann Philipp Zöllner, Philipp S Reif, Karl Martin Klein, Felix Rosenow, Adam Strzelczyk
Eslicarbazepine acetate (ESL) is an anticonvulsant drug approved for the treatment of focal epilepsies, and related to oxcarbazepine and carbamazepine (CBZ), which are also derivatives of the dibenzazepine family. ESL is contraindicated in patients with hypersensitivity reactions to CBZ.We report a patient with frontal lobe epilepsy responding to treatment with ESL without any serious adverse effects after developing a severe skin rash following treatment with CBZ. HLA testing revealed an HLA-A*31:01 haplotype, that increases the risk of CBZ-induced cutaneous reactions...
March 18, 2017: Seizure: the Journal of the British Epilepsy Association
https://www.readbyqxmd.com/read/28329576/5-fluorouracil-induced-exacerbation-of-rosacea
#2
Ellen S Haddock, Philip R Cohen
Background Topical 5-fluorouracil (5-FU) is an antineoplastic antimetabolite used for the treatment of actinic keratosis.Purpose A 66-year-old man with erythematotelangiectatic rosacea and biopsy-confirmed actinic keratoses who experienced a rosacea exacerbation after initiating topical 5-FU treatment of his actinic keratoses is described and this adverse event associated with 5-FU is reviewed.Materials and methods Using PubMed.gov the following terms were searched and relevant citations were assessed: rosacea and 5-fluorouracil...
November 15, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/28327802/in-vitro-and-in-vivo-antileishmanial-activity-of-artemisia-annua-l-leaf-powder-and-its-potential-usefulness-in-the-treatment-of-uncomplicated-cutaneous-leishmaniasis-in-humans
#3
Luz Estella Mesa, Daniel Vasquez, Pierre Lutgen, Iván Darío Vélez, Adriana María Restrepo, Isabel Ortiz, Sara María Robledo
INTRODUCTION: Cutaneous leishmaniasis (CL) is a tropical disease that affects millions of individuals worldwide. The current drugs for CL may be effective but have serious side effects; hence, alternatives are urgently needed. Although plant-derived materials are used for the treatment of various diseases in 80% of the global population, the validation of these products is essential. Gelatin capsules containing dried Artemisia annua leaf powder were recently developed as a new herbal formulation (totum) for the oral treatment of malaria and other parasitic diseases...
January 2017: Revista da Sociedade Brasileira de Medicina Tropical
https://www.readbyqxmd.com/read/28321818/skin-reactions-to-immune-checkpoint-inhibitors
#4
Anisha B Patel, Omar Pacha
The novelty of immune checkpoint inhibitors has only recently led to the characterization of cutaneous adverse events (AEs). This, along with the substantial rate of cutaneous reactions, has left many clinicians without sufficient familiarity to diagnose and treat. In the following chapter, we will review the categories of these drugs, common cutaneous effects, their grading, and management options.
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28295542/unexpected-recalcitrant-course-of-drug-induced-erythema-multiforme-like-eruption-and-interstitial-pneumonia-sequentially-occurring-after-nivolumab-therapy
#5
Hisashi Nomura, Hayato Takahashi, Satsuki Suzuki, Yuichi Kurihara, Shotaro Chubachi, Ichiro Kawada, Hiroyuki Yasuda, Tomoko Betsuyaku, Masayuki Amagai, Takeru Funakoshi
Vemurafenib improves survival of melanoma patients. However, cutaneous side-effects commonly occur in them. Nivolumab and ipilimumab are monoclonal antibodies against programmed death 1 and cytotoxic T-lymphocyte-associated antigen 4, both of which regulate excessive T-cell activation. Although these agents induce antitumor immunity against melanoma, the modified immune condition may result in an unexpected adverse reaction which has not been observed previously. Herein, we report a case who manifested severe erythema multiforme-like eruption with mucosal involvement associated with vemurafenib following nivolumab...
March 11, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28281913/rapidly-progressing-facial-leishmaniasis-effective-treatment-with-liposomal-amphotericin-b-and-a-review-of-the-management-of-old-world-cutaneous-leishmaniasis
#6
Shamim Islam
Cutaneous leishmaniasis (CL), a common condition in many parts of the world, is being increasingly encountered in non-endemic countries secondary to immigration. The clinical manifestations and course can vary substantially, with appropriate management ranging from observation for self-healing lesions to urgent treatment to prevent damaging anatomical and cosmetic sequelae. While there are now several effective medications, optimal therapy is not well defined, and decision-making can be challenged by the location of lesions and various drug issues, including availability, mode of delivery and adverse effects...
March 10, 2017: Paediatrics and International Child Health
https://www.readbyqxmd.com/read/28225974/do-you-know-this-syndrome-hand-foot-syndrome
#7
Cintia Santos Braghiroli, Rodrigo Ieiri, Juliana Polizel Ocanha, Rafael Bispo Paschoalini, Hélio Amante Miot
Hand-foot syndrome is a common cutaneous adverse effect associated with certain systemic chemotherapy drugs. It is characterized by erythema, edema, and burning sensation, especially over palmoplantar surfaces. We report the case of an elderly patient undergoing chemotherapy after a breast cancer surgery who developed symptoms two months after the start of the regimen. There are no studies that explore specific therapies. Suggestive therapy include reducing agent dosage, increasing the interval between cycles, or even stopping chemotherapy...
January 2017: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/28195065/effect-of-econazole-and-benzydamine-on-sensory-neurons-in-culture
#8
S Mathivanan, R de la Torre-Martinez, C Wolf, G Mangano, L Polenzani, C Milanese, A Ferrer-Montiel
Econazole is an anti-mycotic agent widely used for the treatment of cutaneous fungal infections, and for the therapy of vaginal candidiasis. Topical application of this azole is generally safe, although some patients have complained of mild burning sensation/cutaneous irritation and itching, especially when administered intravaginally. The underlying mechanisms responsible of these adverse effects are poorly understood, though they suggest excitation of cutaneous nociceptor terminals. We report that exposure of primary cultures of rat nociceptors to econazole augments neuronal excitability...
December 2016: Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society
https://www.readbyqxmd.com/read/28190531/cutaneous-adverse-effects-of-the-immune-checkpoint-inhibitors
#9
REVIEW
Lindsey K Collins, M Shane Chapman, Joi B Carter, Faramarz H Samie
The immune checkpoint targeted agents, anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and anti-programed cell death 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) inhibitors are frequently associated with cutaneous side effects that are often dose limiting and can lead to discontinuation of therapy. Ipilimumab, a CTLA-4 inhibitor, is most commonly associated with a morbilliform eruption on the trunk and extremities and pruritus. More severe cutaneous toxicities reported include toxic epidermal necrolysis and severe drug rash with eosinophila and systemic symptoms...
December 14, 2016: Current Problems in Cancer
https://www.readbyqxmd.com/read/28165853/biocompatibility-and-characterization-of-polyglycerol-based-thermoresponsive-nanogels-designed-as-novel-drug-delivery-systems-and-their-intracellular-localization-in-keratinocytes
#10
Christian Gerecke, Alexander Edlich, Michael Giulbudagian, Fabian Schumacher, Nan Zhang, Andre Said, Guy Yealland, Silke B Lohan, Falko Neumann, Martina C Meinke, Nan Ma, Marcelo Calderón, Sarah Hedtrich, Monika Schäfer-Korting, Burkhard Kleuser
Novel nanogels that possess the capacity to change their physico-chemical properties in response to external stimuli are promising drug-delivery candidates for the treatment of severe skin diseases. As thermoresponsive nanogels (tNGs) are capable of enhancing penetration through biological barriers such as the stratum corneum and are taken up by keratinocytes of human skin, potential adverse consequences of their exposure must be elucidated. In this study, tNGs were synthesized from dendritic polyglycerol (dPG) and two thermoresponsive polymers...
March 2017: Nanotoxicology
https://www.readbyqxmd.com/read/28164401/skin-depigmentation-associated-with-toceranib-phosphate-in-a-dog
#11
Jacqueline V J Cavalcanti, Andrea Hasbach, Katie Barnes, Rahul B Dange, Jon Patterson, Paulo Vilar Saavedra
BACKGROUND: Drug-induced depigmentation is frequently observed in humans undergoing tyrosine kinase inhibitor therapy, whereas it is not reported in dogs. The skin depigmentation can occur after the first week of treatment and it is reversible within a few weeks after drug discontinuation. OBJECTIVES: To report the clinical and histopathological features of an episode of cutaneous adverse drug reaction associated with short term administration of toceranib phosphate...
February 6, 2017: Veterinary Dermatology
https://www.readbyqxmd.com/read/28162999/health-related-quality-of-life-with-adjuvant-ipilimumab-versus-placebo-after-complete-resection-of-high-risk-stage-iii-melanoma-eortc-18071-secondary-outcomes-of-a-multinational-randomised-double-blind-phase-3-trial
#12
Corneel Coens, Stefan Suciu, Vanna Chiarion-Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A Ascierto, Jon M Richards, Celeste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S Weber, Michele Maio, Andrew Bottomley, Srividya Kotapati, Veerle de Pril, Alessandro Testori, Alexander M M Eggermont
BACKGROUND: The EORTC 18071 phase 3 trial compared adjuvant ipilimumab with placebo in patients with stage III melanoma. The primary endpoint, recurrence-free survival, was significantly longer in the ipilimumab group than in the placebo group. Investigator-reported toxic effects of ipilimumab consisted mainly of skin, gastrointestinal, endocrine, and hepatic immune-related adverse events. Adjuvant treatment with ipilimumab in this setting was approved in October, 2014, by the US Food and Drug Administration based on the results of the primary outcome of this trial...
February 2, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28161548/anti-melasma-codrug-of-retinoic-acid-assists-cutaneous-absorption-with-attenuated-skin-irritation
#13
Pei-Wen Hsieh, Chi-Feng Hung, Chih-Hung Lin, Chang-Wei Huang, Jia-You Fang
Melasma treatment with combined retinoic acid (RA) and hydroquinone (HQ) usually causes unsatisfactory outcomes and safety concerns. This study attempted to evaluate the cutaneous absorption and skin tolerance of the codrug conjugated with RA and HQ via ester linkage. The codrug's permeation of the pig skin was estimated using Franz diffusion cell. The codrug and parent drugs were comparatively examined for anti-inflammatory activity and tyrosinase inhibition. In vivo cutaneous irritation was assessed on nude mouse skin...
February 1, 2017: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/28150343/vemurafenib-induced-toxic-epidermal-necrolysis-is-it-an-emerging-side-effect-of-the-drug
#14
S Kılıç, E Özkaya, C Baykal, S Vatansever
Vemurafenib, a selective inhibitor of the BRAF-kinase used in treatment of metastatic melanoma alone or in combinations,(1) is known to cause various adverse skin reactions such as maculopapular rash, photosensitivity and hyperkeratotic lesions, affecting more than 90% of patients.(1-2) Severe adverse reactions were observed in less than 1% of the patients in clinical trials.(3) However, the increasing number of reported cases of vemurafenib-induced toxic epidermal necrolysis (TEN), a life-threatening severe cutaneous adverse reaction, is striking...
February 1, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28118487/electrochemotherapy-in-the-treatment-of-metastatic-malignant-melanoma-a-prospective-cohort-study-by-inspect
#15
C Kunte, V Letulé, J Gehl, K Dahlstroem, P Curatolo, R Rotunno, T Muir, A Occhini, G Bertino, B Powell, W Saxinger, G Lechner, S-H Liew, R Pritchard-Jones, P Rutkowski, M Zdzienicki, D Mowatt, A J Sykes, A Orlando, G Mitsala, C R Rossi, L Campana, M Brizio, F de Terlizzi, P Quaglino, J Odili
BACKGROUND: Electrochemotherapy (ECT) is an effective local treatment for cutaneous metastasis. Treatment involves the administration of chemotherapeutic drugs followed by delivery of electrical pulses to the tumour. The aim of this study was to investigate the effectiveness of ECT in cutaneous metastases of melanoma and to identify factors which affect (beneficially or adversely) the outcome. METHODS: 13 cancer centres in the International Network for Sharing Practices on Electrochemotherapy (INSPECT) consecutively and prospectively uploaded data to a common database...
January 24, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28105242/skin-toxicity-in-a-patient-with-ovarian-cancer-treated-with-pegylated-liposomal-doxorubicin-a-case-report-and-review-of-the-literature
#16
Joanna Kubicka-Wołkowska, Magdalena Kędzierska, Maja Lisik-Habib, Piotr Potemski
Pegylated liposomal doxorubicin (PLD) is a form of doxorubicin enclosed in pegylated liposomes. In contrast to conventional doxorubicin, PLD is characterized by a lower incidence of cardiotoxicity and myelosuppression. However, it induces specific mucocutaneous side effects, particularly palmar-plantar erythrodysesthesia (PPE). Other dermal manifestations, such as intertrigo-like dermatitis, diffuse follicular rash, melanotic macules, maculopapular rash or recall phenomenon are less common. Mechanisms that lead to skin toxicity remain unclear, however, certain reports indicate that drug excretion in sweat, host-vs...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28095529/open-label-study-evaluating-the-anti-aging-effects-of-a-3-product-2-step-retinol-rejuvenation-system-following-3-months-of-treatment-in-subjects-with-photodamage
#17
Suzanne Bruce, Sylvia Barkovic
BACKGROUND: Photodamage to the skin occurs with exposure to sunlight (UVA or UVB) either intentionally or unintentionally, and can present in a variety of ways. It typically occurs on areas of chronic UV exposure, including the face, ears, and neck. METHODS: We evaluated the effects of a 3-product, 2-step retinol-rejuvenation system containing an exfoliating cleanser, a 0.5% retinol emollient cream, and SPF 30 moisturizing sunscreen used daily for 3 months on the appearance of mild-to-moderate facial photodamage in female subjects...
January 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28071592/development-and-evaluation-of-zinc-phthalocyanine-nanoemulsions-for-use-in-photodynamic-therapy-for-leishmania-spp
#18
Luciana Betzler de Oliveira de Siqueira, Verônica da Silva Cardoso, Igor Almeida Rodrigues, Ana Lúcia Vazquez-Villa, Elisabete Pereira Dos Santos, Bruno da Costa Leal Ribeiro Guimarães, Cristal Dos Santos Cerqueira Coutinho, Alane Beatriz Vermelho, Eduardo Ricci Junior
Photodynamic therapy (PDT) combines light with photosensitizers (PS) for production of reactive oxygen species (ROS) that can kill infectious microorganisms such as bacteria, fungi and protozoa. The application of nanotechnology has enabled the advancement of PDT because many PS are insoluble in water, necessitating a nanocarrier as a physiologically acceptable carrier. Nanoemulsions are efficient nanocarriers for solubilizing liposoluble drugs, like the PS, in water. Cutaneous (CL) and mucocutaneous leishmaniasis (ML) are caused by different species of the genus Leishmania, transmitted to humans by sandfly bites...
February 10, 2017: Nanotechnology
https://www.readbyqxmd.com/read/28069279/masitinib-for-treatment-of-severely-symptomatic-indolent-systemic-mastocytosis-a-randomised-placebo-controlled-phase-3-study
#19
Olivier Lortholary, Marie Olivia Chandesris, Cristina Bulai Livideanu, Carle Paul, Gérard Guillet, Ewa Jassem, Marek Niedoszytko, Stéphane Barete, Srdan Verstovsek, Clive Grattan, Gandhi Damaj, Danielle Canioni, Sylvie Fraitag, Ludovic Lhermitte, Sophie Georgin Lavialle, Laurent Frenzel, Lawrence B Afrin, Katia Hanssens, Julie Agopian, Raphael Gaillard, Jean-Pierre Kinet, Christian Auclair, Colin Mansfield, Alain Moussy, Patrice Dubreuil, Olivier Hermine
BACKGROUND: Indolent systemic mastocytosis, including the subvariant of smouldering systemic mastocytosis, is a lifelong condition associated with reduced quality of life. Masitinib inhibits KIT and LYN kinases that are involved in indolent systemic mastocytosis pathogenesis. We aimed to assess safety and efficacy of masitinib versus placebo in severely symptomatic patients who were unresponsive to optimal symptomatic treatments. METHODS: In this randomised, double-blind, placebo-controlled, phase 3 study, we enrolled adults (aged 18-75 years) with indolent or smouldering systemic mastocytosis, according to WHO classification or documented mastocytosis based on histological criteria, at 50 centres in 15 countries...
February 11, 2017: Lancet
https://www.readbyqxmd.com/read/28057839/niacin-promotes-cardiac-healing-after-myocardial-infarction-through-activation-of-the-myeloid-prostaglandin-d2-receptor-subtype-1
#20
Deping Kong, Juanjuan Li, Yujun Shen, Guihu Liu, Shengkai Zuo, Bo Tao, Yong Ji, Ankang Lu, Michael Lazarus, Richard M Breyer, Ying Yu
Niacin is a well-established drug used to lower cholesterol and prevent cardiovascular disease (CVD) events. However, niacin also causes cutaneous flushing side effects due to release of the proresolution mediator prostaglandin (PG) D2. Recent randomized clinical trials have demonstrated that addition of niacin with laropiprant (a PGD2 receptor subtype 1 [DP1] blocker) to statin-based therapies does not significantly decrease the risk of CVD events but increases the risk of serious adverse events. Here, we tested whether, and how, niacin beneficial effects in vivo myocardial ischemia requires the activation of the PGD2/DP1 axis...
January 5, 2017: Journal of Pharmacology and Experimental Therapeutics
keyword
keyword
109299
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"